文献速递妇科

输卵管前驱病变时代的早期卵巢癌检测:一项系统综述

Early Ovarian Cancer Detection in the Age of Fallopian Tube Precursors: A Systematic Review.
PubMed 文献 · Obstet Gynecol · 2024-01-04

本系统综述检索2008年1月至2023年4月的英文研究,从5523篇文献中筛选131篇原始研究,评估CA 125以外的早期卵巢癌生物标志物。55篇报告了灵敏度、特异度或曲线下面积(AUC),36篇报告至少一种生物标志物特异度≥80%或AUC≥0.9。作者认为多数标志物检测率与CA 125相似或更差,但27.5%(36/131)的文章报告了优于单用CA 125的生物标志物,值得进一步探索。

要点

  • 多数被测试的生物标志物对早期卵巢癌的检测率与CA 125相似或更差。
  • 36/131篇文章报告了灵敏度更优且AUC>0.9的生物标志物。
  • 这些优于CA 125的生物标志物值得进一步探索。

核心结论

  • 尽管多种生物标志物正在卵巢癌中接受测试,但大多数与CA 125相比检测率相似或更差,且在早期疾病中同样存在检测率低的局限。
  • 27.5%的文章(36/131)报告了与单用CA 125相比灵敏度更优且AUC大于0.9的生物标志物,值得进一步探索。

研究设计与样本

  • 系统综述,检索Ovid MEDLINE ALL、EMBASE、Web of Science Core Collection、ScienceDirect、Clinicaltrials.gov和CAB Direct中2008年1月至2023年4月发表的英文研究。
  • 将5523篇相关文章上传至Covidence,两位独立审稿人筛选摘要后确定245篇同行评议原始研究文章进行全文审阅。
  • 全文审阅后确定131篇同行评议原始研究文章纳入本综述。

主要发现

  • 131篇研究中仅55篇报告了灵敏度、特异度或曲线下面积(AUC)。
  • 36篇研究报告至少一种生物标志物特异度≥80%或AUC≥0.9。
  • 27.5%的文章(36/131)报告了与单用CA 125相比灵敏度更优且AUC大于0.9的生物标志物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine biomarkers other than CA 125 that could be used in identifying early-stage ovarian cancer. DATA SOURCES: Ovid MEDLINE ALL, EMBASE, Web of Science Core Collection, ScienceDirect, Clinicaltrials.gov , and CAB Direct were searched for English-language studies between January 2008 and April 2023 for the concepts of high-grade serous ovarian cancer, testing, and prevention or early diagnosis. METHODS OF STUDY SELECTION: The 5,523 related articles were uploaded to Covidence. Screening by two independent reviewers of the article abstracts led to the identification of 245 peer-reviewed primary research articles for full-text review. Full-text review by those reviewers led to the identification of 131 peer-reviewed primary research articles used for this review. TABULATION, INTEGRATION, AND RESULTS: Of 131 studies, only 55 reported sensitivity, specificity, or area under the curve (AUC), with 36 of the studies reporting at least one biomarker with a specificity of 80% or greater specificity or 0.9 or greater AUC. CONCLUSION: These findings suggest that although many types of biomarkers are being tested in ovarian cancer, most have similar or worse detection rates compared with CA 125 and have the same limitations of poor detection rates in early-stage disease. However, 27.5% of articles (36/131) reported biomarkers with better sensitivity and an AUC greater than 0.9 compared with CA 125 alone and deserve further exploration.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Greenwood A, Woodruff ER, Nguyen C, et al. Early Ovarian Cancer Detection in the Age of Fallopian Tube Precursors: A Systematic Review. Obstet Gynecol. 2024. PMID: 38176019. doi:10.1097/AOG.0000000000005496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。